Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget’s disease of bone

[1]  S. Polyzos,et al.  Paget’s disease of bone: emphasis on treatment with zoledronic acid , 2009, Expert review of endocrinology & metabolism.

[2]  S. Polyzos,et al.  Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid , 2009, Supportive Care in Cancer.

[3]  J. Kountouras,et al.  Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. , 2009, Current molecular medicine.

[4]  S. Polyzos,et al.  Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget’s disease of bone , 2008, Journal of Bone and Mineral Metabolism.

[5]  J. Reginster,et al.  Management of patients with Paget’s disease: a consensus document of the Belgian Bone Club , 2008, Osteoporosis International.

[6]  D. Kimmel.  Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates , 2007, Journal of dental research.

[7]  Götz Schlotterbeck,et al.  Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates. , 2007, Chemical research in toxicology.

[8]  M. Phillips.  Risedronate-induced Hepatitis. , 2007, The American journal of medicine.

[9]  H. Atalar,et al.  Hepatotoxicity induced by alendronate therapy , 2007, Osteoporosis International.

[10]  Jacques P. Brown,et al.  Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. , 2005, The New England journal of medicine.

[11]  J. D. Jaureguiberry,et al.  Hépatite aiguë sévère imputable à l'alendronate , 2002 .

[12]  M. Arribas,et al.  Lesión hepatocelular inducida por alendronato , 2001 .

[13]  J. Azuri,et al.  Liver damage due to alendronate. , 2000, The New England journal of medicine.

[14]  R. Lieverse.  Hepatitis after alendronate. , 1998, The Netherlands journal of medicine.

[15]  J. Kanis,et al.  Comparison of three intravenous regimens of clodronate in paget disease of bone , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  J. D. de Jauréguiberry,et al.  [Severe acute hepatitis induced by alendronate]. , 2002, Gastroenterologie clinique et biologique.

[17]  C. de la Serna Higuera,et al.  [Alendronate-induced hepatocellular lesion]. , 2001, Gastroenterologia y hepatologia.

[18]  J. Winkelman,et al.  The American Journal of Medicine , 2000 .

[19]  K. Laitinen,et al.  Clodronate as a Cause of Aminotransferase Elevation , 1999, Osteoporosis International.